INDIANAPOLIS, Sept. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Lauren Marangell, M.D., will join Lilly in November 2007, as a Distinguished Lilly Scholar focusing on depression and related disorders.
"We are delighted to recruit someone with Dr. Marangell's stature and depth of experience to join Lilly," said Jack Harris, M.D., vice president, U.S. medical division. "Lauren brings a national and international reputation in depression and other mood disorders. This experience will allow her to play a key scientific leadership role in our relationships with the U.S. healthcare community and the broader clinical and scientific community, providing quality information regarding Lilly products and research."
Marangell joins Lilly from Baylor College of Medicine where she is Brown Foundation Chair in psychopharmacology of mood disorders, professor of psychiatry with tenure and director of mood disorders research. At Baylor, she developed a state-of-the-art mood disorders research program recognized as one of the most successful in the country. She has held numerous national and international leadership positions and is a scientific reviewer for most major journals in the field. In addition to her success in research, Marangell is well known as a prominent clinician and educator. Among many awards of note, she is a recipient of the "Exemplary Psychiatrist Award" from the National Alliance for the Mentally Ill, and is listed in "Who's Who Among American Educators." She is first author of the "Concise Guide to Psychopharmacology", with coauthor James Martinez, M.D., now also with Lilly.
"I am very excited that Lauren chose to join Lilly," said John Hayes, M.D., vice president, global brand development platform leader - neuroscience. "She is a world-class physician who will provide significant understanding of the external environment and key insights to Lilly's drug development programs. She is an outstanding addition to Lilly's research team."
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved